MEROPENEM FOR INJECTION 1 G — DIN 02462893
MEROPENEM (MEROPENEM TRIHYDRATE) : 1 G · AURO PHARMA INC · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is MEROPENEM FOR INJECTION?
MEROPENEM FOR INJECTION 1 G contains MEROPENEM (MEROPENEM TRIHYDRATE) : 1 G. It is listed in the Health Canada Drug Product Database under DIN 02462893, held by AURO PHARMA INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 20-Oct-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MEROPENEM FOR INJECTION used for?
Meropenem for Injection (meropenem) is indicated for treatment of the following infections when caused by susceptible strains of the designated micro-organisms: Lower Respiratory Tract, Urinary Tract, Intra-abdominal, Gynecologic, Uncomplicated Skin and Skin Structure, Complicated Skin and Skin Structure, Bacterial Meningitis, Bacterial Septicemia.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Meropenem cost around the world?
Meropenem is listed on 9 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Greece | producer price (ex-factory) | 32 | 32 | EUR███.██ |
| Saudi Arabia | public | 15 | 19 | SAR███.██ |
| Italy | ex-factory (classe H) | 15 | 18 | EUR███.██ |
| South Africa | single exit price | 14 | 15 | ZAR███.██ |
| Czechia | max producer price (ex-factory) | 8 | 14 | CZK███.██ |
| Romania | max producer price | 11 | 12 | RON███.██ |
| Bahrain | retail (max) | 2 | 3 | BHD███.██ |
| United Kingdom | hospital | 3 | 3 | GBP███.██ |
| Iceland | max wholesale | 2 | 3 | ISK███.██ |
119 pack listings across 102 brand entries and 9 price bases, refreshed 03 Sep 2026. Ranges span every Meropenem pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Meropenem in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
9 holders have a Canadian DIN containing Meropenem, across 26 DINs, of which 15 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| SANDOZ CANADA INCORPORATED | 4 | 2 | MEROPENEM FOR INJECTION, MEROPENEM FOR INJECTION SDZ | Sourceable in Canada |
| STERIMAX INC | 4 | 2 | MEROPENEM FOR INJECTION, MEROPENEM FOR INJECTION USP | Sourceable in Canada |
| AURO PHARMA INC | 2 | 2 | MEROPENEM FOR INJECTION | Sourceable in Canada |
| B. BRAUN MEDICAL INC | 2 | 2 | MEROPENEM FOR INJECTION USP AND SODIUM CHLORIDE INJECTION USP | Sourceable in Canada |
| EUGIA PHARMA INC. | 2 | 2 | MEROPENEM FOR INJECTION | Sourceable in Canada |
| FRESENIUS KABI CANADA LTD | 2 | 2 | MEROPENEM FOR INJECTION, USP | Sourceable in Canada |
| SUN PHARMA CANADA INC | 2 | 2 | TARO-MEROPENEM | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 2 | 1 | MEROPENEM FOR INJECTION | Sourceable in Canada |
| PFIZER CANADA ULC | 6 | 0 | MEROPENEM FOR INJECTION USP, MERREM | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 1 G |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | null |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Meropenem |
|---|---|
| ATC code | J01DH02 |
| AHFS class | 08:12.07.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02462893 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2462893 |
| Brand name | MEROPENEM FOR INJECTION |
| Generic / active ingredient | MEROPENEM (MEROPENEM TRIHYDRATE) : 1 G |
| Market authorization holder | AURO PHARMA INC |
| Health Canada schedule | Prescription |
| ATC code | J01DH02 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01DH |
| Current status | MARKETED |
| Status date | 20-Oct-2017 |
| Original market date | 2017-10-20 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Meropenem in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by EUGIA PHARMA INC., last seen 21 Aug 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
15 of 26 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| MEROPENEM FOR INJECTION | 500 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02378787 |
| MEROPENEM FOR INJECTION | 1 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | 02493349 |
| MEROPENEM FOR INJECTION | 1 G | POWDER FOR SOLUTION | EUGIA PHARMA INC. | MARKETED | 02528827 |
| MEROPENEM FOR INJECTION | 1 G | POWDER FOR SOLUTION | JAMP PHARMA CORPORATION | MARKETED | 02536374 |
| MEROPENEM FOR INJECTION | 1 G | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02378795 |
| MEROPENEM FOR INJECTION | 500 MG | POWDER FOR SOLUTION | AURO PHARMA INC | MARKETED | 02462885 |
| MEROPENEM FOR INJECTION | 500 MG | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | 02493330 |
| MEROPENEM FOR INJECTION | 500 MG | POWDER FOR SOLUTION | EUGIA PHARMA INC. | MARKETED | 02528819 |
| MEROPENEM FOR INJECTION USP AND SODIUM CHLORIDE INJECTION USP | 500 MG | POWDER FOR SOLUTION | B. BRAUN MEDICAL INC | MARKETED | 02544334 |
| MEROPENEM FOR INJECTION USP AND SODIUM CHLORIDE INJECTION USP | 1 G | POWDER FOR SOLUTION | B. BRAUN MEDICAL INC | MARKETED | 02544342 |
2 · Same class — other molecules in ATC J01DH
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Meropenem | MEROPENEM FOR INJECTION · MEROPENEM FOR INJECTION SDZ · MEROPENEM FOR INJECTION USP · MEROPENEM FOR INJECTION USP AND SODIUM CHLORIDE INJECTION USP · +3 more | 26 | 15 | Yes |
| Ertapenem | ERTAPENEM FOR INJECTION · INVANZ | 9 | 6 | Yes |
| Imipenem And Cilastatin | IMIPENEM AND CILASTATIN FOR INJECTION · IMIPENEM AND CILASTATIN FOR INJECTION USP · IMIPENEM AND CILASTATIN FOR INJECTION, USP · PRIMAXIN 250 · +4 more | 14 | 2 | Yes |
| Meropenem And Vaborbactam | VABOMERE | 1 | 1 | Yes |
| Doripenem | DORIBAX | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J01D
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J01DB | Cefadroxil · Cefalexin · Cefalotin · Cefazolin | 91 | 41 |
| J01DD | Cefixime · Cefotaxime · Cefpodoxime · Ceftazidime · Ceftizoxime · +1 more | 96 | 25 |
| J01DC | Cefaclor · Cefamandole · Cefotetan · Cefoxitin · Cefprozil · +1 more | 135 | 18 |
| J01DE | Cefepime | 10 | 3 |
| J01DF | Aztreonam | 1 | 1 |
| J01DI | Ceftobiprole Medocaril · Ceftolozane And Beta-Lactamase Inhibitor | 2 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is MEROPENEM FOR INJECTION called?
The same molecule, Meropenem, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Ultranem | Latin | Saudi Arabia |
| ARCHIFAR | Latin | Czechia |
| MEROLAB | Latin | Bahrain |
| Meropa | Latin | Saudi Arabia |
| MEROPENEM APTAPHARMA | Latin | Czechia |
| MEROPENEM BAUSCH HEALTH | Latin | Czechia |
| MEROPENEM BRADEX | Latin | Czechia |
| MEROPENEM KABI | Latin | Czechia |
| MEROPENEM KABI. | Latin | Saudi Arabia |
| Meropenem Navamedic | Latin | Iceland |
| MEROPENEM OLIKLA | Latin | Czechia |
| MERONEM | Latin | Czechia |
| MEROPENEM AGMED | Latin | Czechia |
| Meropenem SUN | Latin | Iceland |
| MIRAN | Latin | Bahrain |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.